FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980495919> ?p ?o ?g. }

• W2980495919 abstract "Abstract Allogeneic hematopoietic stem cell transplantation has been proven to be one of few curative treatment options for patients with hematological malignancies. One drawback to this procedure is the development of graft-versus-host disease (GVHD), which can lead to high rates of morbidity and mortality. It is well established that donor T cells are primarily responsible for anti-host activity. Removal or delayed-administration of donor T cells reduces the incidence or severity of GVHD, but is often associated with an increased risk of tumor relapse due to lack of donor T cells that mediate graft-versus-leukemia (GVL) effects. Utilizing CDR3-size spectratype analysis we have focused on identifying host- and tumor-reactive T cells. In this study, a MHC-matched, miHA-mismatched murine transplantation model (B10.BR→CBA) was used to characterize CD8+ T cell repertoire anti-host responses as well as anti-tumor responses to a host-derived myeloid leukemia cell line (MMC6). This model is particularly relevant in that it mimics matched-sibling donor transplants for AML. Spectratype analysis has shown that 14 of 20 Vβ families exhibit biased CDR3-size usage in the B10.BR anti-CBA CD8+ T cell repertoire. In response to MMC6, 7 of 20 Vβ families exhibit biased CDR3-size usage, with Vβ4 and Vβ13 uniquely skewed in the anti-tumor response. We sought to test the ability of spectratype-identified Vβ families, uniquely skewed in the B10.BR CD8+ T cell anti-MMC6 response, to mediate GVL effects in the absence of GVHD in tumor challenged transplant recipients. To this end lethally irradiated (11Gy;split dose) CBA recipients were transplanted with B10.BR ATBM alone, ATBM + B10.BR CD8+ T cells, or ATBM + either B10.BR CD8+ Vβ4+ or Vβ13+ T cells. Duplicate groups of mice received the same transplant conditions and were challenged with MMC6 on day +1 post-transplant. All mice were monitored for symptoms of GVHD and tumor growth. Mice receiving MMC6 in the absence of T cells succumbed to tumor within 30 days post-transplant. Tumor challenged mice receiving CD8+ T cells displayed a statistically significant GVL effect (p<0.0001), however, all eventually succumbed to GVHD. Mice receiving either Vβ4+ or Vβ13+ T cells along with MMC6 displayed minimal GVL effects, with all mice succumbing to tumor challenge. As expected based on the spectratype analysis, mice receiving either Vβ4+ or Vβ13+ T cells in the absence of tumor challenge did not develop any signs of GVHD and survived until termination of the experiment. In order to test the possibility of enhancing the GVL potential, duplicate groups of mice received the same transplant conditions and MMC6 tumor challenge, as above with an additional group that was co-transplanted with CD8+Vβ4+ and Vβ13+ T cells. This combined transplantation of CD8+Vβ4+ and Vβ13+ T cells did not mediate severe lethal GVHD (80% survival). However, together, CD8+Vβ4+ and Vβ13+ T cells significantly prolonged survival (p=0.001) of tumor challenged recipients. Taken together, the results of this study provide proof of principle to support the hypothesis that Vβ spectratype analysis can be used to identify the donor GVH- and GVL-reactive T cells. Furthermore, manipulation of the donor inoculum to enrich for the GVL-reactive and/or deplete the GVH-reactive Vβ families can provide an effective way to separate GVHD from GVL effects." @default.
• W2980495919 created "2019-10-25" @default.
• W2980495919 creator A5001291511 @default.
• W2980495919 creator A5019850176 @default.
• W2980495919 creator A5024437686 @default.
• W2980495919 creator A5045239840 @default.
• W2980495919 creator A5054414219 @default.
• W2980495919 creator A5066086023 @default.
• W2980495919 date "2008-11-16" @default.
• W2980495919 modified "2023-09-29" @default.
• W2980495919 title "Vβ Spectratype-guided Separation of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effects in a MHC-Matched miHA-Mismatched Mouse Model of Hematopoietic Stem Cell Transplantation" @default.
• W2980495919 doi "https://doi.org/10.1182/blood.v112.11.3517.3517" @default.
• W2980495919 hasPublicationYear "2008" @default.
• W2980495919 type Work @default.
• W2980495919 sameAs 2980495919 @default.
• W2980495919 citedByCount "0" @default.
• W2980495919 crossrefType "journal-article" @default.
• W2980495919 hasAuthorship W2980495919A5001291511 @default.
• W2980495919 hasAuthorship W2980495919A5019850176 @default.
• W2980495919 hasAuthorship W2980495919A5024437686 @default.
• W2980495919 hasAuthorship W2980495919A5045239840 @default.
• W2980495919 hasAuthorship W2980495919A5054414219 @default.
• W2980495919 hasAuthorship W2980495919A5066086023 @default.
• W2980495919 hasConcept C109159458 @default.
• W2980495919 hasConcept C126322002 @default.
• W2980495919 hasConcept C154317977 @default.
• W2980495919 hasConcept C167672396 @default.
• W2980495919 hasConcept C202751555 @default.
• W2980495919 hasConcept C203014093 @default.
• W2980495919 hasConcept C207936829 @default.
• W2980495919 hasConcept C2776090121 @default.
• W2980495919 hasConcept C2777408962 @default.
• W2980495919 hasConcept C2778461978 @default.
• W2980495919 hasConcept C2779972918 @default.
• W2980495919 hasConcept C28328180 @default.
• W2980495919 hasConcept C2911091166 @default.
• W2980495919 hasConcept C48556533 @default.
• W2980495919 hasConcept C54355233 @default.
• W2980495919 hasConcept C71924100 @default.
• W2980495919 hasConcept C86803240 @default.
• W2980495919 hasConcept C8891405 @default.
• W2980495919 hasConceptScore W2980495919C109159458 @default.
• W2980495919 hasConceptScore W2980495919C126322002 @default.
• W2980495919 hasConceptScore W2980495919C154317977 @default.
• W2980495919 hasConceptScore W2980495919C167672396 @default.
• W2980495919 hasConceptScore W2980495919C202751555 @default.
• W2980495919 hasConceptScore W2980495919C203014093 @default.
• W2980495919 hasConceptScore W2980495919C207936829 @default.
• W2980495919 hasConceptScore W2980495919C2776090121 @default.
• W2980495919 hasConceptScore W2980495919C2777408962 @default.
• W2980495919 hasConceptScore W2980495919C2778461978 @default.
• W2980495919 hasConceptScore W2980495919C2779972918 @default.
• W2980495919 hasConceptScore W2980495919C28328180 @default.
• W2980495919 hasConceptScore W2980495919C2911091166 @default.
• W2980495919 hasConceptScore W2980495919C48556533 @default.
• W2980495919 hasConceptScore W2980495919C54355233 @default.
• W2980495919 hasConceptScore W2980495919C71924100 @default.
• W2980495919 hasConceptScore W2980495919C86803240 @default.
• W2980495919 hasConceptScore W2980495919C8891405 @default.
• W2980495919 hasLocation W29804959191 @default.
• W2980495919 hasOpenAccess W2980495919 @default.
• W2980495919 hasPrimaryLocation W29804959191 @default.
• W2980495919 hasRelatedWork W1489678151 @default.
• W2980495919 hasRelatedWork W1605624787 @default.
• W2980495919 hasRelatedWork W1678180535 @default.
• W2980495919 hasRelatedWork W1988413416 @default.
• W2980495919 hasRelatedWork W2012314771 @default.
• W2980495919 hasRelatedWork W2031398803 @default.
• W2980495919 hasRelatedWork W2084710449 @default.
• W2980495919 hasRelatedWork W2112107378 @default.
• W2980495919 hasRelatedWork W2158473592 @default.
• W2980495919 hasRelatedWork W2520948604 @default.
• W2980495919 hasRelatedWork W2558977551 @default.
• W2980495919 hasRelatedWork W2560757447 @default.
• W2980495919 hasRelatedWork W2568954227 @default.
• W2980495919 hasRelatedWork W2573438244 @default.
• W2980495919 hasRelatedWork W2586438624 @default.
• W2980495919 hasRelatedWork W2590846694 @default.
• W2980495919 hasRelatedWork W2597104957 @default.
• W2980495919 hasRelatedWork W2895835013 @default.
• W2980495919 hasRelatedWork W2979616225 @default.
• W2980495919 hasRelatedWork W3176922146 @default.
• W2980495919 isParatext "false" @default.
• W2980495919 isRetracted "false" @default.
• W2980495919 magId "2980495919" @default.
• W2980495919 workType "article" @default.